180 related articles for article (PubMed ID: 18486048)
21. Antimycobacterial activities of oxazolidinones: a review.
Sood R; Bhadauriya T; Rao M; Gautam R; Malhotra S; Barman TK; Upadhyay DJ; Rattan A
Infect Disord Drug Targets; 2006 Dec; 6(4):343-54. PubMed ID: 17168800
[TBL] [Abstract][Full Text] [Related]
22. Linezolid for the treatment of drug-resistant infections.
Herrmann DJ; Peppard WJ; Ledeboer NA; Theesfeld ML; Weigelt JA; Buechel BJ
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):825-48. PubMed ID: 19053895
[TBL] [Abstract][Full Text] [Related]
23. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.
Cynamon MH; Klemens SP; Sharpe CA; Chase S
Antimicrob Agents Chemother; 1999 May; 43(5):1189-91. PubMed ID: 10223934
[TBL] [Abstract][Full Text] [Related]
24. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.
Nam HS; Koh WJ; Kwon OJ; Cho SN; Shim TS
Int J Antimicrob Agents; 2009 Jan; 33(1):92-3. PubMed ID: 18789655
[No Abstract] [Full Text] [Related]
25. Linezolid for multidrug-resistant tuberculosis.
Cox H; Ford N; Hughes J; Goemaere E
Lancet Infect Dis; 2013 Jan; 13(1):16. PubMed ID: 23257228
[No Abstract] [Full Text] [Related]
26. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
Brickner SJ; Barbachyn MR; Hutchinson DK; Manninen PR
J Med Chem; 2008 Apr; 51(7):1981-90. PubMed ID: 18338841
[No Abstract] [Full Text] [Related]
27. Update in tuberculosis 2009.
Daley CL
Am J Respir Crit Care Med; 2010 Mar; 181(6):550-5. PubMed ID: 20208041
[No Abstract] [Full Text] [Related]
28. Linezolid for multidrug-resistant tuberculosis - authors' reply.
Chang KC; Leung CC; Daley CL
Lancet Infect Dis; 2013 Jan; 13(1):16-7. PubMed ID: 23257227
[No Abstract] [Full Text] [Related]
29. Linezolid for multidrug-resistant tuberculosis: How should we approach it?
Santin M
Enferm Infecc Microbiol Clin; 2016 Feb; 34(2):83-4. PubMed ID: 26795055
[No Abstract] [Full Text] [Related]
30. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates.
Yip PC; Kam KM; Lam ET; Chan RC; Yew WW
Int J Antimicrob Agents; 2013 Jul; 42(1):96-7. PubMed ID: 23684005
[No Abstract] [Full Text] [Related]
31. Linezolid for extensively drug-resistant tuberculosis.
Cattaneo D; Orlando G; Cordier L
N Engl J Med; 2013 Jan; 368(3):291. PubMed ID: 23323919
[No Abstract] [Full Text] [Related]
32. Linezolid for extensively drug-resistant tuberculosis.
Dhooria S; Agarwal R; Behera D
N Engl J Med; 2013 Jan; 368(3):290-1. PubMed ID: 23323918
[No Abstract] [Full Text] [Related]
33. Linezolid for extensively drug-resistant tuberculosis.
Jaramillo E; Weyer K; Raviglione M
N Engl J Med; 2013 Jan; 368(3):290. PubMed ID: 23323917
[No Abstract] [Full Text] [Related]
34. New TB antibiotic.
AIDS Patient Care STDS; 2003 Aug; 17(8):437-8. PubMed ID: 14619928
[No Abstract] [Full Text] [Related]
35. Thioridazine.
Tuberculosis (Edinb); 2008 Mar; 88(2):164-7. PubMed ID: 18486062
[No Abstract] [Full Text] [Related]
36. Streptomycin.
Tuberculosis (Edinb); 2008 Mar; 88(2):162-3. PubMed ID: 18486061
[No Abstract] [Full Text] [Related]
37. Pyrazinamide.
Tuberculosis (Edinb); 2008 Mar; 88(2):141-4. PubMed ID: 18486055
[No Abstract] [Full Text] [Related]
38. Prothionamide.
Tuberculosis (Edinb); 2008 Mar; 88(2):139-40. PubMed ID: 18486054
[No Abstract] [Full Text] [Related]
39. Levofloxacin.
Tuberculosis (Edinb); 2008 Mar; 88(2):119-21. PubMed ID: 18486047
[No Abstract] [Full Text] [Related]
40. Kanamycin.
Tuberculosis (Edinb); 2008 Mar; 88(2):117-8. PubMed ID: 18486046
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
